The inconsistent expressions related to schizophrenia are newly structured in a recent study by researchers at the Universitas Pompeau Fabra (Barcelona), and Oxford University. Marco Loh, Edmund Rolls and Gustavo Deco have created a dynamical system framework to discuss the disorder, publishing on November 9, 2007 in the journal PLoS Computational Biology.
People with schizophrenia are known to have difficulty in maintaining attention, unstable thoughts, and reduced emotions. Creating a unifying and statistical model to understand these symptoms has always posed a challenge to researchers and clinicians. For this study Loh et al. developed a top-down analytical approach based on the different types of symptoms and related them to instabilities in attractor neural networks in a statistical dynamical framework.
The researchers found that a decrease in the excitatory NMDA-mediated synaptically activated receptor conductances reduces the depth of the attractor basins, therefore reducing the stability of attention in the presence of noise caused by the statistically variable firing of neurons, thus increasing distractibility. This reduced depth in the attractor basins destabilizes the activity at the network level. The cognitive symptoms of schizophrenia (like distractibility) could be caused by this attractor instability in the prefrontal cortex
Loh et al. also found that lower firing rates are produced by reducing the excitatory (NMDA) synaptic conductances, which could account in the orbitofrontal cortex for the negative symptoms associated with schizophrenia, such as a reduction of emotions.
Decreasing both the NMDA and the inhibitory conductances results in switches between attractor states and jumps from spontaneous activity into one of the attractors. This action may cause symptoms related to temporal lobe dysfunction such as delusions and paranoia.
The dynamical framework put forth in this study may better the understanding of the symptoms of schizophrenia, therefore culminating in better treatment for those with the disorder.
Source: Public Library of Science
Related stories:
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Estrogen relieves psychotic symptoms in women with schizophrenia
When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of
Archives of General Psychiatry.
New schizophrenia genes uncovered
(PhysOrg.com) -- Researchers have discovered new genes linked to schizophrenia, it has been revealed. In two papers published in
Nature today (July 30), scientists identify four mutated gene regions that may hold the key to producing new tailor-made drugs to treat the devastating mental illness.
Researchers find a partially shared genetic profile between schizophrenia and bipolar disorder
Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders. A new study scheduled for publication in the July 15th issue of
Biological Psychiatry sought to analyze the patterns of gene expression in the brains of individuals diagnosed with one of these disorders to search for a common "characteristic [genetic] signature."
Incorrectly cleaved protein leads to schizophrenia
Schizophrenia is a disease that strikes an average of 4000 Belgians every year. The causes of this psychiatric disorder are not yet clear. But now, VIB researchers connected to the Katholieke Universiteit Leuven have discovered that a disturbed cleavage of the Nrg-1 protein lies at the basis of the development of the disease. Greater understanding of this molecular process is a first step toward improved diagnosis and more effective treatment of schizophrenia and other related disorders.
Protein on 'speed' linked to ADHD
A genetic change in the dopamine transporter – one of the brain's dopamine-handling proteins – makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in
The Journal of Neuroscience.
Protein marker for schizophrenia risk
A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of
Molecular and Cellular proteomics.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of
Archives of General Psychiatry, one of the JAMA/Archives journals.